Browse diseases

…training cancer-associated fibroblast (CAF) subtypes coexist in pancreatic ductal adenocarcinoma.Objective To develop targeted CAF therapeutic strategies by rep…

… missing variables. Bradley et al developed a BN on survival in pancreatic ductal adenocarcinoma and evaluated the impact of at least two missing variables on t…

… cell populations in the native tissue and in tumours, that is, pancreatic ductal adenocarcinoma (PDAC) and adenosquamous carcinoma of the pancreas (ASCP).Desig…

… the variation in response to neoadjuvant chemotherapy (NAT) in pancreatic ductal adenocarcinoma (PDAC) remain poorly understood. The gut microbiome has been sh…

…oesophageal junction cancers. However, its clinical efficacy in pancreatic ductal adenocarcinoma (PDAC) has been modest, suggesting the presence of regulatory m…

…ive to have a scalable, imaging-based method at hand to predict pancreatic cancer before the patient becomes symptomatic and before a lesion beco…

…Background Failure of conventional imaging to detect pancreatic ductal adenocarcinoma (PDA) at its visually occult pre-diagnostic stage is a primary …

…, pancreatic exocrine insufficiency, diabetes mellitus (DM) and pancreatic ductal adenocarcinoma.Results Buccal (n=238) and rectal (n=249) swabs were analysed b…

…R2 and CCR5 antagonists have demonstrated antitumor activity in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), respectively. This phase 1b…

… to identify pharmaceutical targets whose inhibition suppresses pancreatic ductal adenocarcinoma (PDAC) or potentiates KRAS inhibition, focusing on molecular vu…

…l papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic cancer with highly variable malignant potential. Current understanding…

…Pancreatic ductal adenocarcinoma (PDAC) represents approximately 90% of all malignant tumours in…